CTOs on the Move

Tara Biosystems

www.tarabiosystems.com

 
TARA pioneers predictive tissue models that enable faster, safer, and more reliable development of new medicines. Treatments can make it to market more rapidly, enabling better health and longer life for people.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Tara Biosystems raised $10M on 06/23/2020

Similar Companies

BioCaptiva

Use this space to add a brief description of your project.

parteqinnovations

parteqinnovations is a Kingston, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmuneID

ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. We are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.

Powerpollen

PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices.

Unlearn

Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.